AGMB (AgomAb Therapeutics NV) Research & Development: $16.23 Mil (TTM As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Research & Development?

AgomAb Therapeutics NV AGMB +0.85% 14 Research & Development is $16.23 Mil as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. AgomAb Therapeutics NV's Research & Development for the three months ended in Dec. 2025 was $16.23 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $16.23 Mil.

AgomAb Therapeutics NV  (NAS:AGMB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

AgomAb Therapeutics NV Research & Development Related Terms

AgomAb Therapeutics NV Research & Development Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Research & Development Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.00 20.57 28.69 41.16 57.23

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Research & Development Get a 7-Day Free Trial 0.00 0.00 11.23 0.00 16.23
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $16.23 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Research & Development of $16.23 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Research & Development too high?
AgomAb Therapeutics NV's current Research & Development is $16.23 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Research & Development compare to DNA and ACRS?
AgomAb Therapeutics NV's Research & Development of $16.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Research & Development is $16.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Research & Development of $16.23 Mil. The current Research & Development is $16.23 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Research & Development is $16.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price